Stay
up-to-date
about
RECOVER
Our understanding of Long COVID is constantly evolving with new research findings. Stay informed by reading the latest news and participating in upcoming events.
Results from a recent RECOVER study suggest that adults who have COVID-19 may be more likely to develop a related condition called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).
Six new RECOVER research publications report findings from the initiative’s pathobiology, observational, and electronic health record (EHR) studies.
RECOVER researchers identified 18 symptoms most likely to affect school-age children, 17 symptoms most likely to affect adolescents, with 14 overlapping symptoms most likely to affect both age groups.
Find answers to some of the most frequently asked questions (FAQs) about the first findings from RECOVER’s research on Long COVID in children and adolescents.
Working together during this three-day event, scientists, doctors, government officials, and people affected by Long COVID will help shape the future of RECOVER clinical trials.
Findings from this RECOVER study will inform future efforts to develop tools for diagnosing Long COVID.
NIH-funded analysis of health record data shows severe reinfections often follow severe first infections.
The National Academies of Sciences, Engineering, and Medicine (NASEM) recommends that researchers, healthcare professionals, and government agencies adopt its new working definition of Long COVID to help ease the suffering of millions of people.
During the June 25th RECOVER Research Review (R3) Seminar, researchers presented details about RECOVER-SLEEP, which included two trials focused on identifying potential treatments for sleep disturbances. Researchers also shared details about RECOVER-ENERGIZE, which included one trial focused on potential treatments for exercise intolerance and one trial examining potential treatments for post-exertional malaise. All the trials were recruiting adults experiencing one or more of these symptoms after having COVID. The presentation also included updates on other RECOVER clinical trials in progress.
Media InquiriesAre you a member of the media or press? Please direct inquiries to the RECOVER@nih.gov inbox. Please place "MEDIA INQUIRY" in your subject line.